Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CPA3 | P15088 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.44 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426274 | 0.85 | CYP1A2 (0.50) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL5426376 | 0.82 | CTSS (0.60) | — | |
| SCHEMBL8535169 | 0.80 | CYP1A2 (0.54) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL30543817 | 0.79 | CYP1A2 (0.56) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL7322955 | 0.76 | CYP1A2 (0.66) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL7322961 | 0.76 | CYP1A2 (0.66) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL7322967 | 0.76 | CYP1A2 (0.66) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL6841478 | 0.75 | CYP1A2 (0.51) | CYP1A2CPA3FOLH1CPA1GRIA2 | |
| SCHEMBL5870627 | 0.75 | CYP1A2 (0.51) | CYP1A2CPA3FOLH1CPA1GRIA2 | |
| SCHEMBL9456007 | 0.75 | GRIA2 (0.57) | CYP1A2CPA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CYP1A2 3406/4885CPA3 22/4885FOLH1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.